ReSECT
  • Home
  • About
  • Data Model
    • Operative Log
    • Lung Resection
    • Thymus
  • Participation
    • Users
    • Departments
  • Audit
    • Users
    • Departments
    • ESTS
  • Reports
    • Resection & Approach
    • Postop. Course
    • Lung Cancer
  • Projects
  • Applications
  • News

Resection & Approach

Reports · Lung Resection · ReSECT

Resection & Approach

Which resections are performed, through which approach, and how often minimally invasive surgery is converted to open surgery.

Resection & ApproachPostop. CourseLung Cancer
AboutResectionApproachResection & approachConversionData updated on 2 November 2026

8,687

Procedures since 2023

84%

Minimally invasive approach (VATS or RATS)

65%

Of the resections are lobectomies

7.9%

Of minimally invasive procedures converted to open

About this report

How to read the charts

The report describes the surgical activity of the Lung Resection Process since 2023.

01

All the content of this report considers the date of surgery, not the date of data entry.

02

Every chart has a tab for the overall period and another one for each year.

03

Each category keeps its colour in all the charts of the report.

Resection

Type of resection

Share of each type of resection in every year, and procedures accumulated over time.

Annual

Accumulated

Approach

Type of approach

Share of each surgical approach in every year, and procedures accumulated over time.

Annual

Accumulated

Resection & approach

The approach of each resection

Surgical approach used in each type of resection. Percentages add up to 100% within each resection.

  • Overall
  • 2026
  • 2025
  • 2024
  • 2023

Conversion

Conversion to open surgery

Minimally invasive procedures (VATS or RATS) that had to be converted to open surgery. Wedge resections are not considered.

By approach

By type of resection


Reports

Keep exploring

01

Postop. Course

Complications, level of care and postoperative stay.

Report

02

Lung Cancer

Diagnosis, staging, lymphadenectomy and disease free survival.

Report

Supported by

Medtronic

::ReSECT
Clinical Trials.gov, NCT05600569

ReSECT Web Project
Designed & Developed by ReSECT